Radiopharmaceutical ContentRadiopharmaceutical Kit Content
| Tc-99m-Succimer (DMSA) |
2,3-dimercaptosuccinic acid 1.2 mg/ml Stannous Chloride 0.42 mg/ml SWFI qs 2.2 ml |
| Tc-99m-Mertiatide (MAG3) |
Betiatide 1 mg Stannous chloride 0.05 mg Sodium tartrate dihydrate 40 mg Lactose monohydrate 20 mg |
| Tc-99m Exametazime (Ceretec) |
Exametazime 0.5 mg Stannous chloride 7.6 μg Sodium chloride 4.5 mg |
| Tc-99m Bicisate (Neurolite) |
Vial A: Bicisate dihydrochloride 0.9 mg Stannous chloride 0.072 mg Mannitol 0.36 mg Buffer Vial B: Sodium phosphate dibasic 4.1 mg Sodium phosphate monobasic 0.46 mg SWFI qs 1 ml |
| Tc-99m MAA |
Human albumin aggregates 1.0 mg Human albumin 10.0 mg Sodium chloride 10.0 mg Stannous chloride 0.7 mg |
| Tc-99m MDP |
Medronate disodium 10.0 mg Stannous chloride 0.5 mg |
| Tc-99m PYP |
Sodium pyrophosphate 10.0 mg Sodium trimetaphosphate 30.0 mg Stannous chloride 0.95 mg |
| Tc-99m Sestamibi (Cardiolite) |
Tetrakis (2-methoxy isobutyl isonitrile) Copper (I) tetrafluoroborate 1.0 mg Sodium citrate dihydrate 2.6 mg L-Cysteine hydrochloride monohydrate 1.0 mg Mannitol 20.0 mg Stannous chloride 0.075 mg |
| Tc-99m Tetrofosmin (Myoview) |
Tetrofosmin 0.23 mg Stannous chloride 30 μg Disodium sulphosalicylate 0.32 mg Disodium D-gluconate 1.0 mg Sodium hydrogen carbonate 1.8 mg |
| Ultra-Tag RBC |
Reaction Vial: Stannous chloride 50 μg Sodium citrate dihydrate 3.67 mg Dextrose, anhydrous 5.50 mg Syringe I: Sodium hypochlorite 0.6 mg in SWFI Syringe II: Citric acid, monohydrate 8.7 mg Sodium citrate, dihydrate 32.5 mg Dextrose, anhydrous 12.0 mg in SWFI |
| Tc-99m HSA |
Human albumin 21 mg Stannous tartrate 0.23 mg |
| Tc-99m DTPA |
Pentetate calcium disodium 20 mg Stannous chloride 0.15 mg |
| Tc-99m GH (Glucoheptonate) |
Gluceptate sodium 200 mg Stannous chloride 0.06 mg |
| Tc-99m SC (Sulfur Colloid) |
Reaction Vial: Sodium thiosulfate 2.0 mg Sodium EDTA 2.3 mg Gelatin 18.1 mg Syringe A: HCl (0.148M) 1.5 ml Syringe B: Sodium dihydrogen phosphate 38.8 mg Sodium hydroxide 11.1 mg SWFI qs 1.5 ml |
| Tc-99m DISIDA (Disofenin) |
Disofenin 20.0 mg Stannous chloride 0.24 mg |
| Tc-99m Mebrofenin |
Mebrofenin 45.0 mg Stannous fluoride 0.54 mg Methylparaben 5.2 mg Propylparaben 0.58 mg |
| Tc-99m Apcitide (AcuTect) |
Bibapcitide 100 μg Sodium glucoheptonate 75 μg Stannous chloride 89 μg |
| Tc-99m Depreotide (NeoTect) |
Depreotide 50 μg Sodium glucoheptonate 5 mg Stannous chloride 50 μg Disodium EDTA 100 μg |
| Tc-99m Arcitumomab (CEA-Scan) |
Arcitumomab 1.25 mg Stannous chloride 0.29 mg Potassium sodium tartrate, sodium acetate, sodium chloride, acetic acid, hydrochloric acid, sucrose |
| Tc-99m Nofetumomab (Verluma) |
(1) Isopropyl alcohol (2) Phenthiolate ligand (3) Glacial acetic acid: 0.2N HCl 1:7 (4) 1M Sodium bicarbonate buffer (5) Nofetumomab Fab fragment |
| Tc-99m Sulesomab (LeukoScan) |
Sulesomab 0.31 mg Stannous chloride 0.22 mg Sodium chloride, Potassium sodium tartrate, Sodium acetate, Sucrose |
| Tl-201 Chloride |
Per ml: Thallous chloride Tl-201 1 mCi Sodium chloride 9 mg Benzyl alcohol 9 mg |
| Sodium Chromate Cr-51 |
Per ml: Sodium chromate Cr-51 100 μCi Benzyl alcohol 6 mg |
| Xe-133 gas |
5% Xe-133 gas; 95% carbon dioxide (10 mCi and 20 mCi) |
| Co-57 Cyanocobalamin |
Capsules NLT 0.5 μCi/μg (0.5 – 1.0 μCi per capsule |
| I-125 HSA injection |
Iodinated I-125 albumin 6.67 μCi (0.8 mg) Sodium chloride 9.0 mg Dibasic sodium phosphate 122 μg Monobasic potassium phosphate 64 μg Guanidine 0.5 μg Benzyl alcohol 0.9% v/v per ml |
| I-125 Iothalamate |
Per ml: Sodium iothalamate I-125 1 mg Benzyl alcohol 9 mg SWFI qs 1 ml |
| I-131 Sodium Iodide capsule |
15, 25, 50, or 100μCi in polyethylene glycol and sodium thiosulfate in a thin film on inside surface |
| I-131 Sodium Iodide solution |
7, 14,28 ,70 or 106 mCi at 7.05 mCi/ml. Each ml contains disodium EDTA. |
| I-131 MIBG (Iobenguane I-131) |
Diagnostic (per ml): Ammonium dihydrogen phosphate 0.045 mg Benzyl alcohol 9 mg Copper sulfate 0.002 mg Iobenguane I-131 9.25 mg SWFI, qs 1 ml Therapeutic (per ml): Ammonium dihydrogen phosphate 0.7 mg Copper sulfate 0.02 mg Glucose 50 mg Iobenguane I-131 SWFI, qs 1 ml |
| I-123 Sodium Iodide capsule |
Sodium iodide I-123 100 μCi Sodium hydroxide 20 μg Sucrose 1 gm |
| Ga-67 Gallium Citrate |
Per ml: Gallium-67 chloride 2 mCi Sodium citrate 2 mg Sodium chloride 6.8 mg Benzyl alcohol 9 mg |
| In-111 DTPA |
Per ml: Pentetate Indium-111 Disodium 1 mCi Pentetic acid 20 μg Sodium bicarbonate |
| In-111 Oxyquinoline (Oxine) |
Per ml: In-111 (.50 mCi/μg) 1 mCi Oxyquinoline 50 μg Polysorbate 80 100 μg HEPES buffer in 0.75% saline 6 μg |
| In-111 Penretreotide (OctreoScan) |
Pentrtreotide 10.0 mg Gentisic acid 2.0 mg Trisodium citrate 4.9 mg Citric acid 0.37 mg Inositol 10.0 mg |
| In-111 Capromab (ProstaScint) |
Reaction Vial: Capromab pendetide 0.5 mg Sodium phosphate buffered saline 1.0 ml Buffer Vial: Sodium acetate 82.0 mg SWFI 2.0 ml |
| In-111 Satumomab (OncoScint) |
Reaction Vial: Satumomab pentetide 1.0 mg Sodium phosphate buffered saline 2.0 ml Buffer Vial: Sodium acetate 136 mg SWFI 2.0 ml |
| F-18 Fludeoxyglucose |
“Black Box” synthesis |
| P-32 Sodium Phosphate solution |
P-32 Sodium phosphate 0.67 mCi Sodium acetate 1.6 mg Sodium chloride 0.9% |
| P-32 Chromic Phosphate |
P-32 Chromic phosphate 1.0 mCi Dextrose 300 mg Benzyl alcohol 20 mg Sodium acetate 1 mg |
| Sr-89 Chloride (Metastron) |
Per ml: Strontium-89 chloride 10.9-22.6 mg SWFI 1 ml |
| Sm-153 Lexidronam (Quadramet) |
Per ml: EDTMP 35.0 mg Calcium hydroxide 5.3 mg Sodium hydroxide 14.1 mg Samarium-153 50 mCi (5-46 μg) |
| Rb-82 Chloride |
Generator produced |
| In-111 Ibritumomab (Zevalin-diagnostic) |
Zevalin Vial: Ibritumomab tiuxetan 3.2 mg Sodium Chloride 0.9% 2.0 ml Sodium Acetate Vial: Sodium acetate 13.6 mg SWFI 2.0 ml Formulation Buffer Vial: Albumin (Human) 750 mg Sodium chloride 76 mg Sodium phosphate dibasic 21 mg Pentetic acid 4 mg Potassium phosphate monobasic 2 mg Potassium chloride 2 mg SWFI 10 ml In-111 chloride sterile solution |
| Y-90 Ibritumomab (Zevalin-therapeutic) |
As above Y-90 chloride sterile solution |